risperidone has been researched along with Hyperactivity, Motor in 19 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 9.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 7.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Ninety-two patients with early stage schizophrenia treated with risperidone entered this 16-week, double blind, randomized, placebo-controlled clinical trial." | 5.19 | Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. ( Guo, X; Liu, F; Ou, J; Ruan, Y; Wu, R; Xie, L; Xu, X; Yang, J; Yang, L; Yang, S; Zeng, Y; Zhang, B; Zhang, L; Zhao, J; Zheng, Y, 2014) |
| "Several clinical reports have suggested that the mirtazapine-induced augmentation of risperidone activity may effectively improve the positive, negative and some cognitive symptoms of schizophrenia." | 3.78 | Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. ( Rogóż, Z, 2012) |
| "Risperidone is an antipsychotic drug approved for use in children, but little is known about the long-term effects of early-life risperidone treatment." | 1.39 | Adult rats treated with risperidone during development are hyperactive. ( Bardgett, ME; Colemire, KR; Franks-Henry, JM; Griffith, MS; Juneau, KR; Marczinski, CA; Stevens, RM, 2013) |
| " Pharmacokinetic study showed that PDs were quickly metabolized to paliperidone to take effect in the treatment of schizophrenia in rats after i." | 1.36 | Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats. ( Li, Y; Meng, Q; Su, Z; Sui, C; Sun, F; Teng, L; Yuan, L; Zhang, C, 2010) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rogóż, Z | 1 |
| Bardgett, ME | 3 |
| Franks-Henry, JM | 1 |
| Colemire, KR | 1 |
| Juneau, KR | 1 |
| Stevens, RM | 2 |
| Marczinski, CA | 1 |
| Griffith, MS | 2 |
| Gao, J | 2 |
| Li, M | 2 |
| Qiao, J | 1 |
| Shu, Q | 1 |
| Zhang, Q | 1 |
| Hu, G | 1 |
| Liu, F | 1 |
| Guo, X | 1 |
| Wu, R | 1 |
| Ou, J | 1 |
| Zheng, Y | 1 |
| Zhang, B | 1 |
| Xie, L | 1 |
| Zhang, L | 1 |
| Yang, L | 1 |
| Yang, S | 1 |
| Yang, J | 1 |
| Ruan, Y | 1 |
| Zeng, Y | 1 |
| Xu, X | 1 |
| Zhao, J | 1 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Gannon, MA | 1 |
| van der Staay, FJ | 1 |
| Pouzet, B | 1 |
| Mahieu, M | 1 |
| Nordquist, RE | 1 |
| Schuurman, T | 1 |
| Marchese, G | 1 |
| Casu, G | 1 |
| Casti, P | 1 |
| Spada, GP | 1 |
| Pani, L | 1 |
| Hidaka, N | 1 |
| Suemaru, K | 1 |
| Araki, H | 1 |
| Sun, F | 1 |
| Su, Z | 1 |
| Sui, C | 1 |
| Zhang, C | 1 |
| Yuan, L | 1 |
| Meng, Q | 1 |
| Teng, L | 1 |
| Li, Y | 1 |
| Celikyurt, IK | 1 |
| Kayir, H | 1 |
| Ulak, G | 1 |
| Erden, FB | 1 |
| Ulusoy, GK | 1 |
| Uzbay, TI | 1 |
| Budisteanu, M | 1 |
| Papuc, SM | 1 |
| Tutulan-Cunita, A | 1 |
| Budisteanu, B | 1 |
| Arghir, A | 1 |
| Kovacs, N | 1 |
| Balas, I | 1 |
| Janszky, J | 1 |
| Simon, M | 1 |
| Fekete, S | 1 |
| Komoly, S | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Hartfield, AW | 1 |
| Moore, NA | 1 |
| Clifton, PG | 1 |
| Baum, KT | 1 |
| O'Connell, SM | 1 |
| Lee, NM | 1 |
| Hon, JC | 1 |
| Demb, HB | 1 |
| Stalman, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia[NCT01493622] | Phase 4 | 78 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for risperidone and Hyperactivity, Motor
| Article | Year |
|---|---|
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; | 2014 |
18 other studies available for risperidone and Hyperactivity, Motor
| Article | Year |
|---|---|
Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice.
Topics: Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Dextroamphetamine; Disease Models, An | 2012 |
Adult rats treated with risperidone during development are hyperactive.
Topics: Animals; Antipsychotic Agents; Female; Hyperkinesis; Learning; Male; Rats; Rats, Long-Evans; Risperi | 2013 |
Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Dibenzocycloheptenes; Dopam | 2013 |
Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley rats: a possible D2 receptor mediated phenomenon?
Topics: Aging; Animals; Antipsychotic Agents; Avoidance Learning; Conditioning, Psychological; Dopamine Agon | 2014 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
Delayed yet persistent effects of daily risperidone on activity in developing rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sc | 2016 |
The d-amphetamine-treated Göttingen miniature pig: an animal model for assessing behavioral effects of antipsychotics.
Topics: Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship | 2009 |
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Chemistry, Pharmaceutical; | 2009 |
Serotonin-dopamine antagonism ameliorates impairments of spontaneous alternation and locomotor hyperactivity induced by repeated electroconvulsive seizures in rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Dopamine Antagonists; Electroshock; Haloperidol; Hy | 2010 |
Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Electrocardiography; Exc | 2010 |
Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats.
Topics: Alcoholism; Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Central Nervous System Dep | 2011 |
Novel clinical finding in MECP2 duplication syndrome.
Topics: Child; Child Development; Chromosomes, Human, X; Cognitive Behavioral Therapy; Early Intervention, E | 2011 |
Status dystonicus in tardive dystonia successfully treated by bilateral deep brain stimulation.
Topics: Adolescent; Antipsychotic Agents; Clonazepam; Deep Brain Stimulation; Disability Evaluation; Electro | 2011 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats.
Topics: Animals; Antipsychotic Agents; Cocaine; Dibenzothiazepines; Dopamine Antagonists; Dopamine Uptake In | 2006 |
Effects of risperidone on locomotor activity and spatial memory in rats with hippocampal damage.
Topics: Animals; Drug Evaluation, Preclinical; Hippocampus; Hyperkinesis; Injections; Locomotion; Male; Memo | 2006 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Prevention of relapse in schizophrenia.
Topics: Antipsychotic Agents; Haloperidol; Humans; Hyperkinesis; Psychomotor Agitation; Risperidone; Schizop | 2002 |